RAP-219 for Partial Seizures

(FOCUS 2 Trial)

This trial tests a new drug, RAP-219, to determine if it can safely and effectively reduce the frequency of partial seizures in adults. Participants will receive either a low or medium dose of RAP-219 or a placebo (a harmless pill with no active drug). The trial seeks adults who have had focal epilepsy (a type of seizure that starts in one area of the brain) for at least two years, are currently taking 1-3 anti-seizure medications, and can track their seizures daily using an e-diary. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to the potential availability of a new treatment.

The trial allows participants to continue taking between 1 and 3 antiseizure medications as maintenance. You won't need to stop your current antiseizure medications, but you should not be taking more than three.

Research has shown that RAP-219 is generally safe for people with focal seizures. Earlier studies found that most participants experienced only mild side effects and tolerated the medication well. Importantly, no reports of serious adverse effects emerged from the drug. While some minor issues might occur, RAP-219 is considered safe for most individuals. Overall, the evidence suggests that RAP-219 could be a promising option for those dealing with focal seizures.¹²³⁴⁵

RAP-219 is unique because it offers a novel approach to treating partial seizures with an oral tablet form, which might enhance convenience and adherence compared to some existing treatments that require more complex administration. Unlike the standard treatments that primarily modulate neurotransmitter activity, RAP-219 could potentially target a different mechanism, which might lead to improved control over seizures. Researchers are excited about RAP-219 as it could provide an alternative for those who do not respond well to current medications, possibly offering a new option with different side effect profiles.

Research has shown that RAP-219 may help treat focal seizures. In earlier studies, patients taking RAP-219 experienced a significant drop in seizures, with an average decrease of 77.8%. Notably, 24% of patients had no seizures at all over an 8-week period, and 72% of participants had at least a 50% reduction in seizure frequency. In this trial, participants will receive either a low or medium dose of RAP-219, or a placebo. These results suggest that RAP-219 could effectively reduce the number of focal seizures.¹²³⁴⁵